Trials / Completed
CompletedNCT00934050
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELND005 (scyllo-inositol) | Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks After 15Dec2009: ELND005 250 mg PO BID for 48 weeks |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-07-08
- Last updated
- 2019-10-21
- Results posted
- 2015-05-13
Locations
38 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00934050. Inclusion in this directory is not an endorsement.